Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2139466
Reference Type
Journal Article
Title
Systemic inflammation and COPD - The Framingham Heart Study
Author(s)
Walter, RE; Wilk, JB; Larson, MG; Vasan, RS; Keaney, JF, Jr; Lipinska, I; O'Connor, GT; Benjamin, EJ
Year
2008
Is Peer Reviewed?
Yes
Journal
Chest
ISSN:
0012-3692
EISSN:
1931-3543
Volume
133
Issue
1
Page Numbers
19-25
Language
English
PMID
17908709
DOI
10.1378/chest.07-0058
Web of Science Id
WOS:000252385600008
Abstract
BACKGROUND:
The current paradigm for the pathogenesis of COPD includes an ultimately maladaptive local inflammatory response to environmental stimuli. We examined the hypothesis that systemic inflammatory biomarkers are associated with impaired lung function, particularly among those with extensive cigarette smoking.
METHODS:
Using data from the Framingham Heart Study, we examined cross-sectional associations of systemic inflammatory biomarkers (CD40 ligand [CD40L], intercellular adhesion molecule [ICAM]-1, interleukin [IL]-6, monocyte chemoattractant protein-1, P-selectin, and myeloperoxidase, in addition to C-reactive protein) to impaired lung function.
RESULTS:
IL-6 was consistently associated with impaired lung function; a 1-SD higher concentration of IL-6 was associated with a 41-mL lower FEV(1) (95% confidence interval [CI], - 61 to - 20) and a borderline 15% higher odds of COPD (odds ratio, 1.15; 95% CI, 0.99 to 1.34). Additionally, P-selectin was associated with lower FEV(1) levels; after adjusting for the other biomarkers, a 1-SD higher concentration of P-selectin predicted an FEV(1) that was on average 19 mL lower (95% CI, - 37 to 0). Including the biomarkers individually as sole exposures in the models generally strengthened the impaired lung function/biomarker association; the relations of ICAM-1 to FEV(1), and ICAM and CD40L to COPD became significant. The observed associations did not vary significantly with smoking history, except that the association between CD40L and COPD appeared greater in individuals with more extensive smoking histories.
CONCLUSIONS:
Among participants in the Framingham Heart Study, systemic inflammation was associated with lower levels of pulmonary function. Further research into the role of systemic inflammation in the development of pulmonary dysfunction is merited.
Keywords
CD40 ligand; forced expiratory volume; inflammation; intercellular adhesion molecule-1; interleukin-6; monocyte chemoattractant protein-1; mycloperoxidase; p-selectin; pulmonary disease; chronic obstructive
Tags
NAAQS
•
ISA-NOx (2016)
Considered
Health Effects
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity